View Older Stories View More Recent Stories
-
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health (JAGX) Announces Approval of All Proposals at June 2024 Annual Meeting of Stockholders
-
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
-
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
